New Insight with Dr. Veeral Sheth

Don’t Miss a Beat

Crisis Point

Revolutionizing Atopic Dermatitis

Ryan Livingston joined the MJH Life Sciences team in March of 2025, shortly after graduating from TCNJ with a bachelor’s degree in English. He enjoys creative writing, reading, and scuba diving. He can be reached at rlivingston@mjhlifesciences.com.

An analysis of results from the Coronary Artery Risk Development in Young Adults (CARDIA) study has indicated that both 

 improvement in young adults and better cardiovascular health in middle age were independently associated with lower midlife risk of 

Investigators utilized Life’s Essential 8 (LE8), an updated version of the quantitative metric for monitoring and measuring CVH created by the American Heart Association (AHA) in 2010. The original consisted of seven core features: healthy diet, participation in physical activity, nicotine avoidance, healthy weight, and healthy blood pressure, blood lipids, and blood glucose. The eighth factor, healthy sleep, was added in 2022.

“Most literature on the association between cardiovascular health (CVH) and incident cardiovascular disease (CVD) and mortality has relied on single midlife measurements,” wrote James Walker, BA, department of preventative medicine, Northwestern University Feinberg School of Medicine, and colleagues. “Understanding how cumulative CVH over time influences later-life CVD and mortality may aid early prevention.”

The CARDIA study, a longitudinal, community-based cohort study that ran from 1985-2020, involved 5115 participants between 18-30 years. Walker and colleagues quantified CVH from these data according to the AHA’s LE8 score, with each measure scored on a scale of 0-100 points. Overall LE8 score was calculated as the unweighted mean of all 8 metrics.

Investigators established a primary outcome of CVD incident through 2022, with a secondary outcome of all-cause mortality. 45 years was marked as the start of outcome follow-up time. Of the original 5115 participants, 4832 had the necessary follow-up data for inclusion in the study – those who had experienced CVD events or died before age 45 were also excluded.

Participants were divided into 4 quartiles based on cumulative LE8 score: the team assessed the relationship between LE8 scores before and after age 45 using multivariable Cox proportional hazards regression models. Outcomes were fitted into the quartile model as a categorical variable (percent by quartile: 0-25

) and as a continuous variable (per 20 points higher LE8 point x years). A model was fitted with the covariates of cumulative LE8 score and a single LE8 score measure at 45 years to assess the relationship between them.

The 4832 included CARDIA participants, of which 2690 (55.7%) were female, had a mean cumulative LE8 score from 18-45 years of 2018.8 (95.0) point x years. The difference between mean Q1 and Q4 cumulative LE8 scores was marked as 626 point x years. Q4 participants exhibited the most favorable CVH health metric levels, including BMI, blood pressure, blood lipid levels, nicotine exposure, serum glucose value, etc.) followed sequentially by Q3, 2, and 1.

Investigators also noted that, during the 14.2 years of follow-up, 285 CVD deaths and 323 deaths from all causes occurred. Participants with the highest quartile of cumulative LE8 score had the least mortality and CVD events during follow-up; each lower quartile exhibited a higher risk of developing mortality or CVD.

Compared with the lowest quartile, 2, 3, and 4 all had significantly lower hazard ratios (HRs) for CVD (Q2 HR, 0.44; 95% CI, .32-.61; Q3 HR, .26; 95% CI, .18-38; Q4 HR, .12; 95% CI, .07-.21) and mortality (Q2 HR, .51; 95% CI, .36-.71; Q3 HR, .38; 95% CI, .26-.55; Q4 HR, .29; 95% CI, .18-.45) after age 45. Cumulative and improvement of LE8 scores from 18-45 years also associated significantly with lower CVD risk.

The team notes that these data indicate a greater cumulative time at higher CVH during young adulthood correlates with lower risk of CVD development in later years.

“Point x years and points up could be useful ways to communicate and promote CVH to young adult patients,” Walker and colleagues wrote. “Given the recent promising research on harnessing gamification to encourage patients to change their health behaviors, further research could examine the potential for using point x years and points up in the LE8 paradigm to improve young adult CVH.”

Walker J, Won D, Guo J, et al. Cumulative Life’s Essential 8 Scores and Cardiovascular Disease Risk. JAMA Cardiol. Published online April 23, 2025. doi:10.1001/jamacardio.2025.0630

Lloyd-Jones DM, Allen NB, Anderson CAM, et al. Life’s essential 8: Updating and enhancing the American Heart Association’s construct of Cardiovascular Health: A presidential advisory from the American Heart Association. 

. 2022;146(5). doi:10.1161/cir.0000000000001078

Articles

The CARDIA study highlights the importance of maintaining cardiovascular health (CVH) from young adulthood to middle age to reduce midlife cardiovascular disease (CVD) risk. Utilizing the American Heart Association's Life’s Essential 8 (LE8) metric, which includes healthy sleep, the study found that higher cumulative LE8 scores correlate with lower CVD and mortality risks. Participants with better CVH metrics, such as BMI and blood pressure, had significantly lower hazard ratios for CVD and mortality. The study suggests using gamification to promote CVH improvements in young adults.

Using the American Heart Association’s Life’s Essential 8 model, researchers indicated that preventative action early in life can reduce chances of developing cardiovascular disease later.

News

news page, resources on the topics of disease- and specialty-specific medical news and expert insight can be found. Content includes articles, interviews, videos, podcasts, and breaking news on health care research, treatment, and drug development.

Clinical

clinical page is a resource for content on every specialty, disease, and topic available on our medical news site.

Cardiology

Cardiology condition center page is a comprehensive resource for clinical news and insights on cardiovascular and cardiometabolic diseases. This page consists of interviews, articles, podcasts, and videos on the research, treatment and development of therapies for heart disease and cardiovascular events, as well as associated diabetes, renal failure, and more...

Atherosclerotic Cardiovascular Disease

Cardiovascular Health in Youth Linked to Lower Disease Risk in Adulthood

Connor Iapoce is the assistant managing editor for 

joining the MJH Life Sciences team in April 2021. He graduated from The College of New Jersey with a degree in Journalism and Professional Writing. He enjoys listening to records, going to the movies, and playing with his cat, Squish. You can reach him at 

Interim safety and efficacy data from the first-in-human study of the SpyGlass Drug Delivery Platform showed key improvements in vision and intraocular pressure (IOP) outcomes at 18 months in eyes with 

mild to moderate open-angle glaucoma or ocular hypertension

2025 American Society of Cataract and Refractive Surgery (ASCRS) Annual Meeting

, the monofocal intraocular lens (IOL) with mounted sustained-release bimatoprost implant achieved statistically and clinically significant reductions in IOP across all patient groups, with no reports of device-related adverse events.

“In the US, 5 million cataract surgeries are performed annually, with 20% occurring in patients who also have increased intraocular pressure caused by open-angle glaucoma or ocular hypertension,” said Malik Kahook, MD, co-founder of SpyGlass Pharma and a professor of ophthalmology at the University of Colorado Anschutz Medical Campus.

 “Our compelling 18-month results highlight the potential long-term benefits of the SpyGlass Drug Delivery Platform for these patients.”

A total of 23 eyes treated across 75 mcg, 150 mcg, and 300 mcg doses were included in the single-center prospective cohort study and examined at regular intervals, with a planned three-year follow-up. Investigators measured safety and efficacy using best-corrected distance visual acuity (BCDVA), IOP, and slit lamp examination.

Upon analysis, at 18 months, the BCDVA improved from a baseline range of 20/30 to 20/100 to a range of 20/16 to 20/30, while IOP was reduced from a baseline of 25.1 ± 2.5 mmHg to 14.1 ± 2.6 mmHg (

 <.0001). Investigators identified no statistically significant differences in IOP lowering across the three dosage groups, and all patients remained off topical IOP-lowering medication at the 18-month follow-up visit.

“The promising improvement in visual acuity, along with the clinically meaningful reduction in IOP, reinforce our confidence in the platform, and we look forward to sharing these data with the ophthalmic community at ASCRS,” Kahook added.

SpyGlass completed enrollment in its US Phase 1/2 study and continues to follow patients from its first-in-human trial, with plans to share long-term data soon as it works with the US Food and Drug Administration (FDA) to advance toward Phase 3 trials and commercial approval.

“We continue to see the SpyGlass Drug Delivery Platform poised to reimagine the treatment paradigm by addressing the unmet need of long-term drug delivery while also utilizing a familiar implantation technique for cataract surgeons,” said Patrick Mooney, chief executive officer of SpyGlass Pharma.

 “This promising dataset bolsters the potential for long-term durability of both visual outcomes and IOP-lowering efficacy. We look forward to providing further data updates from this ongoing study."

Robles MA, Robles PJ, Sussman G, Kahook MY, et al. Visual Outcomes of an Intraocular Lens with a Sustained-Release Bimatoprost Implant in Eyes with Open Angle Glaucoma or Ocular Hypertension. Presented at: 2025 American Society of Cataract and Refractive Surgery (ASCRS) Annual Meeting. April 25-28, 2025. Los Angeles, CA.

Spyglass Pharma, Inc. Spyglass pharma presents 18-month data demonstrating compelling visual acuity results with their IOL-Mounted Innovative Drug Delivery Platform. GlobeNewswire News Room. April 24, 2025. Accessed April 25, 2025. 

https://www.globenewswire.com/news-release/2025/04/24/3067371/0/en/SpyGlass-Pharma-Presents-18-Month-Data-Demonstrating-Compelling-Visual-Acuity-Results-with-Their-IOL-mounted-Innovative-Drug-Delivery-Platform.html

Interim data from the first-in-human study of the SpyGlass Drug Delivery Platform demonstrated significant improvements in vision and intraocular pressure (IOP) in patients with mild to moderate open-angle glaucoma or ocular hypertension. The study, presented at the 2025 ASCRS Annual Meeting, showed that the monofocal intraocular lens with a sustained-release bimatoprost implant achieved clinically significant IOP reductions without device-related adverse events. The study included 23 eyes across three dosage groups, with improvements in best-corrected distance visual acuity and IOP reduction maintained at 18 months.

Innovative drug delivery platform shows significant vision improvement and IOP reduction in glaucoma patients, promising a new treatment paradigm.

Conference

 conference coverage page features articles, videos, and expert-led live coverage from major medical meetings throughout the year.

Ophthalmology

Ophthalmology page, resources on the topics of medical news and expert insight into ophthalmic disease can be found. Content includes articles, interviews, videos, podcasts, and breaking news on eye disease research, treatment, and drug development.

SpyGlass Bimatoprost Drug Delivery Platform Improves Vision at 18 Months

Jeffrey H. Levenson, MD is the founding director and managing partner of Levenson Eye Associates.

Benefit of Clobetasol Propionate Post-Cataract Surgery, With Jeffrey Levenson, MD

Twice-daily clobetasol propionate ophthalmic suspension 0.05% for 14 days achieved rapid and sustained reduction of ocular inflammation and pain after 

, compared with placebo, in new results from two pivotal Phase 3 trials.

, clobetasol propionate ophthalmic suspension revealed quicker and greater visual acuity (VA) improvement and a similar adverse event profile to placebo, suggesting its effectiveness following ocular surgery.

“It offers the potential for a brief course of potent anti-inflammatory therapy that’s easy to comply with, just twice a day, and no need for a taper,” presenting investigator Jeffrey H. Levenson, MD, founding director and managing partner of Levenson Eye Associates, told 

. “It’s patient and doctor-friendly and might enable fewer post-operative visits, offering potential benefits over the modalities we now use.”

 approved clobetasol propionate ophthalmic suspension 0.05% for post-operative inflammation and pain following ocular surgery in March 2024, marking the first new steroid approved for eye care in 15 years.

Dual multicenter, randomized, double-masked, placebo-controlled, parallel-group studies randomized patients undergoing routine unilateral uncomplicated cataract surgery to receive clobetasol propionate ophthalmic suspension (n = 366) or placebo (n = 382) for 14 days after surgery. The primary efficacy endpoint included the proportion of patients with an anterior chamber cell (ACC) count of 0 at Days 4 to 15, with secondary endpoints including ocular pain grade at each follow-up visit.

More patients treated with clobetasol propionate ophthalmic suspension achieved an ACC of 0 at Days 8 to 15, compared with placebo (26.5% vs. 6.8%; 

 <.001), as well as a significantly higher proportion with ocular pain grade of 0 at Days 4 to 15 (71.6% vs. 27.7%; 

Those treated with clobetasol propionate ophthalmic suspension also experienced a more rapid rate of improvement and greater magnitude of improvement in the BCVA by Day 4, while significantly fewer required rescue medication (6.3% vs. 44.8%; 

 <.001). Further data showed similar increases in intraocular pressure (IOP), with only 1.4% of the clobetasol propionate ophthalmic suspension seeing increases.

Clobetasol propionate ophthalmic suspension was well-tolerated with few adverse events and similar corneal endothelial cell count (ECC) changes versus placebo.

“Patients don't mention their drops, other than to say that they're doing well and they're seeing well, and they're pleased with their surgical outcomes,” Levenson told 

. “The best comment from a patient with regards to a procedure is nothing but pleasure and seeing better.”

Levenson reports no relevant disclosures.

Levenson JH, Korenfeld MS, Silverstein SM, et al. Pivotal Phase 3 Studies of Clobetasol Propionate Ophthalmic Suspension 0.05% for Post-Cataract Surgery Inflammation and Pain. Presented at: 2025 American Society of Cataract and Refractive Surgery (ASCRS) Annual Meeting. April 25-28, 2025. Los Angeles, CA.

Formosa Pharmaceuticals and AIMMAX Therapeutics receive FDA approval for Clobetasol propionate ophthalmic suspension 0.05%, for the treatment of post-operative inflammation and pain following ocular surgery. March 4, 2024. Accessed April 25, 2025. 

https://www.prnewswire.com/news-releases/formosa-pharmaceuticals-and-aimmax-therapeutics-receive-fda-approval-for-clobetasol-propionate-ophthalmic-suspension-0-05-for-the-treatment-of-post-operative-inflammation-and-pain-following-ocular-surgery-302079089.html

Videos

Jeffrey Levenson, MD, discusses the sustained reduction of ocular inflammation and pain post ocular surgery with clobetasol propionate ophthalmic suspension.

Surgery

The HCPLive surgery page is a resource for medical news and expert insights on invasive medicine. This page features expert-led coverage, articles, videos and research on the therapies and development of treatments for surgery, and more.

Katherine E. Talcott, MD, is a vitreoretinal surgeon at Cole Eye Institute, Cleveland Clinic.

Managing IOP After Intravitreal Injections, With Katherine Talcott, MD

As the demand for intravitreal injections rises with increasing cases of 

, including age-related macular degeneration (AMD), diabetic retinopathy, and retinal vein occlusions (RVO), so does concern over their impact on intraocular pressure (IOP). At the 2025 

American Society of Cataract and Refractive Surgery (ASCRS) Annual Meeting

, Katherine Talcott, MD, a retina specialist at the Cole Eye Institute, Cleveland Clinic, addressed a key question: Do these injections raise IOP—and if so, what does that mean for long-term patient care?

Short-term IOP spikes post-injection are well-documented, while many patients tolerate this well, others report transient blurred vision or discomfort.

“IOP increases in the short term,” Talcott told 

. “The eye has a fixed volume, and we're injecting an additional volume, so it's common for pressure to go up. It’s not uncommon for my patients to say their vision is a little blurry or irritated for a period afterwards. I make sure that patients can see my hands moving after the injection, and if they can’t, I recheck the pressure.”

Talcott emphasizes tailored follow-up: after checking vision clarity immediately post-injection, she monitors for pressure spikes in select patients, sometimes using pressure-lowering drops or considering a glaucoma workup. More nuanced risks arise with steroid-based injections, which can cause delayed IOP increases.

However, Talcott pointed to available data—ranging from clinical trials to large registry studies using the IRIS registry—indicating that long-term pressure increases affect only a small minority of patients, often fewer than 5%.

With newer therapies entering the market, including high-volume anti-vascular endothelial growth factor (VEGF) agents and complement inhibitors for geographic atrophy, the interplay between injection volume and IOP remains an area of active observation. Talcott stressed the importance of ongoing vigilance as treatment intervals extend and drug types evolve.

She also welcomed growing cross-specialty collaboration in ophthalmology, noting the value of retina specialists participating in broader meetings like ASCRS. Looking ahead, Talcott expressed optimism for continued innovation in the field, citing upcoming trial data and evolving treatment strategies for AMD and geographic atrophy.

“It'll be interesting to see how this plays out, and then some of our patients, like our AMD patients, might be getting anti-VEGF injections, but also might be getting complement inhibitor injections,” Talcott told HCPLive. “It’ll be interesting to see how that sort of shakes out, but good to remain vigilant about checking.”

Relevant disclosures for Talcott include AbbVie, Apellis, Bausch & Lomb, and Zeiss.

Talcott KE. Does IOP Really Increase with Intravitreal Injections?. Presented at: 2025 American Society of Cataract and Refractive Surgery (ASCRS) Annual Meeting. April 25-28, 2025. Los Angeles, CA.

Katherine Talcott, MD, discuss the impact of intravitreal injections on intraocular pressure, emphasizing monitoring and patient safety in treatment.

Age-Related Macular Degeneration

age-related macular degeneration condition center page is a comprehensive resource for clinical news and insights on retina disease. This page consists of interviews, articles, podcasts, and videos on the research, treatment and development of therapies for patients with AMD.

Diabetic Macular Edema

The HCPLive diabetic macular edema page is a comprehensive resource for clinical news and insights on DME. This page consists of interviews, articles, podcasts, and videos on the research, treatment and development of therapies for the leading cause of blindness, and more.

Young shared with his real-world experiences with etranacogene dezaparvovec gene therapy.

A Positive Outlook on Gene Therapy for Hemophilia B Post-Discontinuation, with Guy Young, MD

Pfizer recently announced that it was discontinuing development and commercialization of fidanacogene elaparvovec an adeno-associated virus (AAV) vector-based gene therapy for the treatment of hemophilia B.

The therapy was approved only 1 year ago, in April 2024, under the name Beqvez.

Upon approval, fidanacogene elaparvovec joined pioneer gene therapy etranacogene dezaparvovec-drlb, approved by the FDA under the name Hemgenix for the same indication in 2022.

HCPLive spoke with Guy Young, MD, Director, Hemostasis and Thrombosis Program, Children’s Hospital of Los Angeles, and Professor of Pediatrics, Keck School of Medicine of University of Southern California, who served as an investigator on the etranacogene dezaparvovec program and who has administered it in the commercial setting, to learn more about his outlook on gene therapy in the hemophilia B field amidst the discontinuation.

Young stressed that his outlook on gene therapy in the field remained positive. He shared his experiences with etranacogene dezaparvovec in the real world and the patient and clinician reception.

“I think that the field is ready. We're seeing more and more patients receiving this,” Young said. “I think with gene therapy, there was all this excitement, and then it… kind of died off. But I think we're at that point where, where the tide is going to turn… the future products will be either different or better, or offer things that Hemgenix cannot offer… I think that hemophilia patients are excited about and are ready for products that can provide them the potential for getting cured.”

Young’s relevant disclosures included Genentech/Roche, Grifols, and Takeda, BioMarin, Novo Nordisk, Sanofi, Spark, Takeda, and UniQure.

Santhosh C. Pfizer stops commercialization of hemophilia gene therapy Beqvez. Reuters. February 21, 2025. Accessed April 25, 2025. 

https://www.reuters.com/business/healthcare-pharmaceuticals/pfizer-says-it-will-end-global-development-gene-therapy-beqvez-nikkei-reports-2025-02-20/

U.S. FDA Approves Pfizer’s BEQVEZ™ (fidanacogene elaparvovec-dzkt), a One-Time Gene Therapy for Adults with Hemophilia B. News release. Pfizer. April 26, 2024. Accessed April 25, 2025. https://www.businesswire.com/news/home/20240425269649/en/U.S.-FDA-Approves-Pfizer%E2%80%99s-BEQVEZ%E2%84%A2-fidanacogene-elaparvovec-dzkt-a-One-Time-Gene-Therapy-for-Adults-with-Hemophilia-B

Johnson V. FDA approves first gene therapy for hemophilia B. HCP Live. November 23, 2022. Accessed April 25, 2025. https://www.hcplive.com/view/fda-approves-first-gene-therapy-hemophilia-b.

Hematology

Christina Y. Weng, MD, MBA, is a professor and the Alice R. McPherson Retina Research Foundation Chair in Ophthalmology at Baylor College of Medicine.

Christina Y. Weng, MD, breaks down emerging gene therapy programs poised to change how retina specialists treat chronic eye disease.

Reshaping Retinal Care With Gene Therapy Programs, With Christina Y. Weng, MD

Tim Smith joined the MJH Life Sciences team as an assistant editor for HCPLive in August 2022. He graduated from UC Berkeley with a degree in political science, working in multimedia journalism as a staff writer prior to joining MJH. In his spare time, he enjoys reading, watching TV, listening to podcasts, and rock climbing. You can contact him at 

In this letter to the editor, investigators highlight the issues faced by patients with alopecia areata and the common barriers to JAK inhibitor access.

Alopecia

Dermatology

The HCPLive dermatology page is a resource for medical news and expert insights on skin disease. This page features expert-led coverage, articles, videos and research on the therapies and development of treatments for dermatologic conditions, and more.

Study Highlights Disparities in Access to JAK Inhibitors for Alopecia Areata

Chelsie Derman is an associate editor for 

who covers psychiatry, sleep medicine, geriatrics, migraine, and allergy. She joined MJH Life Sciences in September 2023 after graduating from The College of New Jersey with a bachelor’s degree in journalism and professional writing. In her free time, she enjoys creative writing and reading.

A systematic review suggests introducing denatured or baked egg under supervision could reduce the burden of strict allergen avoidance.


Allergy

Allergy condition center page is a comprehensive resource for clinical news and insights on allergic and inflammatory diseases. This page consists of interviews, articles, podcasts, and videos on the research, treatment and development of therapies for food and seasonal allergies, as well as allergic asthma and related conditions.

Graded Exposure to Baked Egg May Improve Tolerance in Patients with Egg Allergy

Norouzi reflects on significant advances in glomerular disease from Q1 and looks ahead to what the rest of 2025 may have to offer.

Nephrology

The HCPLive nephrology page is a resource for medical news and expert insights on kidney disease. This page features expert-led coverage, articles, videos and research on the therapies and development of treatments in nephrology, and more.

IgA Nephropathy

The HCPLive Berger disease page is a resource for medical news and expert insights on IgA nephropathy. This page features expert-led coverage, articles, videos and research on the therapies and development of treatments in Berger disease, and more.

C3 Glomerulopathy

The HCPLive C3 glomerulopathy page is a resource for medical news and expert insights on C3G. This page features expert-led coverage, articles, videos and research on the therapies and development of treatments in C3G, and more.

What’s New and What’s Next in Glomerular Disease Care, with Sayna Norouzi, MD

A major factor of type 2 diabetes mellitus, dyslipidemia can potentially be prevented by closely monitoring lipid profiles.

Dyslipidemia

Connection Found Between Angiopoietin-Like Proteins 3 and 4 and Dyslipidemia

Victoria Johnson joined the MJH Life Sciences in 2020 and has written for NeurologyLive, CGTLive, and now HCPLive. You can reach her at vjohnson@mjhlifesciences.com

The 25-mg brensocatib group showed statistically significant changes in FEV1 decline as well as pulmonary exacerbations.

Pulmonology

Infectious Disease condition center page is a comprehensive resource for clinical news and insights on respiratory health. This page consists of interviews, articles, podcasts, and videos on the research, treatment and development of therapies for asthma, COPD, interstitial lung disease, COVID-19, and more.

COPD

COPD condition center page, resources on the topics of medical news and expert insight into chronic obstructive pulmonary disease can be found. Content includes articles, interviews, videos, podcasts, and breaking news on COPD research, treatment, and drug development.

Brensocatib Improved Outcomes, Slowed Decline in People With Bronchiectasis

Parent company VivaVision plans to request a type C meeting with the US Food and Drug Administration.

Uveitis

The HCPLive uveitis page is a comprehensive resource for clinical news and insights on chorioretinitis. This page consists of interviews, articles, podcasts, and videos on the research, treatment and development of therapies for eye inflammation, and more.

VVN461 Trial Topline Results Announced for Non-Infectious Anterior Uveitis

These data point to the necessity of incorporating disease burden in patient interactions and decision making for those under the age of 18 years.

Atopic Dermatitis

Atopic Dermatitis condition center page, audiences can find a variety of coverage mediums for medical news and updates, including articles, video interviews, podcasts, and breaking news on dermatitis research, treatment, and drug development.

Study Highlights Patient-Reported Disease Burdens in Children with Atopic Dermatitis

Abigail Brooks is an assistant editor for 

She joined MJH Life Sciences in August 2023 shortly after graduating from Monmouth University where she earned her BA in Communication with a concentration in Public Relations/Journalism and later an MA in Interactive Digital Media. She enjoys traveling, running, and reading books. She can be reached at abrooks@mjhlifesciences.com.

Prophylactic treatment with IV magnesium led to a lower risk of cisplatin-associated AKI in patients with cancer undergoing cisplatin chemotherapy.

Chronic Kidney Disease

Prophylactic IV Magnesium Linked to Lower Cisplatin-Associated AKI Risk

Simple choices like improving diet and increasing exercise can influence a healthy individual’s risk of developing cardiovascular disease.

Heart Failure

The HCPLive heart failure page is a resource for medical news and expert insights on HF. This page features expert-led coverage, articles, videos and research on the therapies and development of treatments for heart disease, reduced and preserved ejection fraction, and more.

Stroke

On the HCPLive stroke page, resources on the topics of medical news and expert insight into CVA can be found. Content includes articles, interviews, videos, podcasts, and breaking news on stroke medicine, and more.

Latest News

Cardiovascular Health in Youth Linked to Lower Disease Risk in Adulthood

SpyGlass Bimatoprost Drug Delivery Platform Improves Vision at 18 Months

Benefit of Clobetasol Propionate Post-Cataract Surgery, With Jeffrey Levenson, MD

Managing IOP After Intravitreal Injections, With Katherine Talcott, MD

A Positive Outlook on Gene Therapy for Hemophilia B Post-Discontinuation, with Guy Young, MD